David A. Rizzieri, MD David A. Rizzieri, MD

David A. Rizzieri, MD

Cell Therapy and Hematologic Malignancies Specialist

4.9 out of 5  (120 ratings, 20 reviews)
Duke Health Provider What's this?
919-668-1027 Adult Bone Marrow Transplant 919-684-8964 Hematologic Malignancies
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.

Below are the plans currently accepted in 2018. There are some changes to the plans accepted beginning January 1, 2019. More information will become available on PlanForDuke.com.

Click to see a list of accepted insurance plansHide accepted insurance plans
Contact
919-668-1002 Office number
919-668-1091
Fax number
919-668-1002 Office
919-668-1091 Fax number
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.

Below are the plans currently accepted in 2018. There are some changes to the plans accepted beginning January 1, 2019. More information will become available on PlanForDuke.com.

Click to see a list of accepted insurance plansHide accepted insurance plans

Contact
919-668-1002 Office
919-668-1091 Fax number
WHERE I PROVIDE CARE
Profile
ABOUT ME

My practice focuses on the care of patients with leukemia or lymphoma. I enjoy working with patients and their families providing for the full continuum of their care needs. From initial evaluation, through planning multidisciplinary treatments, offering investigational study options, and marrow/stem cell, cord blood, or haploidentical transplantation, my practice is able to provide a thorough management plan for all such treatment needs. I am confident that the multidisciplinary team of physicians, nurses, advanced practice providers, pharmacists, radiation, and medical oncologists that we provide assure the best outcomes possible for our patients.

LANGUAGES I SPEAK
English
LEARN MORE ABOUT ME
Training
EDUCATION
MD, University of Rochester School of Medicine and Dentistry (New York), 1991
RESIDENCY
Internal Medicine, Strong Memorial Hospital, University of Rochester Medical Center (New York), 1991-1994
FELLOWSHIP
Hematology and Oncology, Duke University Medical Center, 1994-1997
BOARD CERTIFICATION
American Board of Internal Medicine, Medical Oncology
Clinical Focus and Research
MY RESEARCH INTERESTS

I focus on developing new therapies for patients with leukemia or lymphoma. I am a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee and NCI Leukemia Working Groups. I serve as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last two national studies for Burkitt’s lymphoma, as well as the current leukemia in under 60-year-olds study. I have led our team’s novel approaches for the care of patients using monoclonal antibodies with non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients with hematologic malignancies using haplo-identical, as well as matched, donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. I have led the development of anti-stromal therapy in lymphoma using new antibodies targeting the stromal protein, tenascin, for which a patent is pending, and first in-human studies targeting acute myelogenous leukemia by linking diphtheria to an antibody to the IL-3 receptor (now in phase 3).

Ratings and Reviews

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more about our survey process. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Overall provider rating
4.9 out of 5 (120 ratings, 20 reviews)
PATIENT REVIEWS
Patient comments are gathered from our Press Ganey Patient Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
  • AbbVie
  • Allos Therapeutics, Inc. (Spectrum Pharmaceuticals)
  • Celgene Corporation
  • Cephalon, Inc. (Teva Pharmaceuticals)
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals
  • Novartis
  • Pfizer Inc.
  • Sanofi-Aventis
  • incyte
  • seattle genetics